Key facts
- Notable investors include GP Capital (Shanghai).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Joint Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Joint Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Joint Biosciences
Operator of a biotechnology company intended to offer a modern integrated platform facility for research and development of molecular biology, virus, and cell therapy drugs. The company engages in the development of combination therapeutic drugs for solid tumors with expertise in the fields of virology, immunology, tumor, and translational medicine, virus and cell therapy drugs, and much more.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- jointbiosciences.com/
- Ownership
- Privately Held (backing)
Joint Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Joint Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Joint Biosciences in its N-PORT filings yet. We sweep new filings monthly.